No title
Background: Clinicopathologic stage is still the main parameter to evaluate the prognosis of newly diagnosed colorectal cancer (CRC) patients. Although molecular markers have been suggested for follow up of treated CRC patients, their complete clinical application is still under evaluation. Materials and methods: To evaluate the association of immune-related genes with CRC prognosis and survival,
